0000000000417204

AUTHOR

Johannes Brachmann

showing 6 related works from this author

Impact of Structural Heart Disease on the Acute Complication Rate in Atrial Fibrillation Ablation: Results from the German Ablation Registry

2013

Acute Complication Rate in AF Ablation Introduction Catheter ablation (CA) has emerged as a widespread therapeutic option in the treatment of atrial fibrillation (AF). Currently, no safety data with regard to the impact of the underlying structural heart diseases (SHD) are available. We sought to assess the risk for acute and long-term complications during CA of AF in relation to underlying SHD. Methods and Results We included 6,211 patients in a prospective registry undergoing CA of AF in 41 nationwide centers. All patients were divided into 4 groups according to the underlying heart disease: No SHD (69.4%), hypertensive heart disease (HHD) (12.0%), coronary artery disease (CAD) (15.1%), a…

medicine.medical_specialtyUnivariate analysisHeart diseasebusiness.industrymedicine.medical_treatmentCardiomyopathyAtrial fibrillationCatheter ablationOdds ratiomedicine.diseaseHypertensive heart diseaseCoronary artery diseasePhysiology (medical)Internal medicinemedicineCardiologyCardiology and Cardiovascular MedicinebusinessJournal of Cardiovascular Electrophysiology
researchProduct

Five-Year Results of the Bioflow-III Registry:Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent

2018

Abstract Purpose We aimed to assess long-term safety and performance of the Orsiro sirolimus-eluting coronary stent with biodegradable polymer in a large unselected population and in pre-specified subgroups. Methods BIOFLOW-III is a prospective, multicenter, international, observational registry with follow-up visits scheduled at 6 and 12 months, and at 3 and 5 years ( NCT01553526 ). Results 1356 patients with 1738 lesions were enrolled. Of those, 392 (28.9%) declined to participate in the study extension from 18 months to 5 years, 37 (2.7%) withdrew consent, and 89 (6.6%) were lost to follow-up. At 5-years, Kaplan-Meier estimates of target lesion failure, defined as a composite of cardiac …

MaleTarget lesionTime Factorsmedicine.medical_treatmentMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsAbsorbable ImplantsBiodegradable polymerProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionAngioplasty Balloon Coronaryeducation.field_of_studyDiabetesDrug-Eluting StentsGeneral MedicineCoronary artery stenosisMiddle AgedTreatment OutcomeDrug-eluting stentFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyPolyestersPopulationHybrid stentProsthesis Design03 medical and health sciencesDiabetes mellitusCoronary stentmedicineHumanseducationAgedSirolimusbusiness.industryCoronary ThrombosisStentCardiovascular Agentsmedicine.diseaseConfidence intervalSurgeryCoronary OcclusionChronic DiseaseDrug-eluting stentbusiness
researchProduct

Complication Rates of Catheter Ablation of Atrial Fibrillation in Patients Aged ≥75 Years versus <75 Years-Results from the German Ablation Regist…

2017

Age-Related Complication Rates in AF AblationIntroduction Despite a rising demand for catheter ablation (CA) of atrial fibrillation (AF) in an elderly population, complication and success rates are not fully elucidated. We sought to compare complication rates of CA of AF in patients ≥75 versus <75 years of age. Methods and Results Patients with symptomatic, drug-refractory AF were prospectively enrolled from January 2007 to 2010 in this multicenter study. A total of 4,449 patients, group 1 ≥75 years and group 2 <75 years (n = 227, age 77.3 ± 2.2 vs. 59.7 ± 9.8 years, 52.0% vs. n = 4,222, 68.9% male, CHA2DS2-VASc-Score 3.7 ± 1.0 vs. 1.7 ± 1.2; P < 0.001, respectively), with paroxysmal AF (59…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCatheter ablationAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseaseAblationSurgery03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineCohortmedicineCardiologyIn patient030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessComplicationStrokeJournal of Cardiovascular Electrophysiology
researchProduct

TCT-350 Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real World Setting - First 400 Subjects at 12-month Follow-up of t…

2018

The aim of this registry is to investigate the clinical performance and long-term safety of the Resorbable Magnesium Scaffold (Magmaris) (BIOTRONIK AG, Buelach, Switzerland) in a real-world setting. Up to 2,054 subjects in up to 120 clinical sites in Europe, Asia, and Asia-Pacific countries will

Scaffoldmedicine.medical_specialtybusiness.industry0206 medical engineeringClinical performance02 engineering and technology030204 cardiovascular system & hematology020601 biomedical engineering03 medical and health sciences0302 clinical medicineInternal medicineCohortMedicineCardiology and Cardiovascular MedicinebusinessMonth follow upJournal of the American College of Cardiology
researchProduct

Survival and quality of life after early discharge in low-risk pulmonary embolism.

2020

IntroductionEarly discharge of patients with acute low-risk pulmonary embolism requires validation by prospective trials with clinical and quality-of-life outcomes.MethodsThe multinational Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE) single-arm management trial investigated early discharge followed by ambulatory treatment with rivaroxaban. The study was stopped for efficacy after the positive results of the predefined interim analysis at 50% of the planned population. The present analysis includes the entire trial population (576 patients). In addition to 3-month recurrence (primary outcome) and 1-year overall mortality, …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPatient subgroups030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesMedicineHumansProspective StudieseducationEarly dischargeAgededucation.field_of_studyRivaroxabanbusiness.industrymedicine.diseaseInterim analysisPatient Discharge3. Good healthPulmonary embolism030228 respiratory systemAmbulatoryQuality of LifeFemalebusinessPulmonary Embolismmedicine.drugThe European respiratory journal
researchProduct

Recommendations of the European Cardiac Arrhythmia Society Committee on Device Failures and Complications

2006

Recommendations of the European Cardiac Arrhythmia Society Committee on Device Failures and Complications MASSIMO SANTINI,* JOHANNES BRACHMANN,† RICCARDO CAPPATO,‡ WYN DAVIES,§ JERONIMO FARRE,‖ SAMUEL LEVY,¶ AURELIO QUESADA,# RENATO P. RICCI,** EDWARD ROWLAND,†† NEIL SULKE‡‡ From *San Filipo Neri Hospital, Rome, Italy, †Klinikum Coburg, Germany, ‡Policlinico S. Donato, Milan, Italy, §St. Mary Hospital, London, UK, ‖Fundacion Jimenez Diaz, Madrid, Spain, ¶Hopital Nord des Bourrellys, Marseille, France, #Hospital General University of Valencia, Spain, **San Filippo Neri Hospital, ††St. George Medical School, London, UK, ‡‡Eastbourne General Hospital, Sussex, UK

Pacemaker Artificialmedicine.medical_specialtybusiness.industryMedical schoolCardiac arrhythmiaEquipment DesignGeneral MedicineDefibrillators ImplantableInternal medicinemedicineCardiologyHumansEquipment FailureGeneral hospitalCardiology and Cardiovascular MedicinebusinessHumanitiesPacing and Clinical Electrophysiology
researchProduct